Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

 In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the meeting of Board of Directors of Lincoln Pharmaceuticals Limited (the "Company") held on today, i.e. December 7, 2019 and considered and decided following business; 1. It is decided to withdraw the Scheme of amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Company") as approved by the Board of Directors in its meeting held on September 19, 2019 and 2. Approved the Scheme of Amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Company") ("Scheme"), subject to all requisite approval. The Appointed Date for the Scheme is April 01, 2019.
07-12-2019
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Outcome Of The Board Meeting For Intimation Of Scheme Of Amalgamation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the meeting of Board of Directors of Lincoln Pharmaceuticals Limited (the "Company") held on today, i.e. December 7, 2019 and considered and decided following business; 1. It is decided to withdraw the Scheme of amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Company") as approved by the Board of Directors in its meeting held on September 19, 2019 and 2. Approved the Scheme of Amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Company") ("Scheme"), subject to all requisite approval. The Appointed Date for the Scheme is April 01, 2019.
07-12-2019
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Scheme Of Amalgamation

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/12/2019 ,inter alia, to consider and approve This is to inform you that applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, December 07, 2019 at the Registered Office of the Company inter-alia to consider the following: 1. To Withdrawal the In-principle application and Draft Scheme filed with NSE, earlier approved by the Board of Directors in its meeting held on September 19, 2019, on the ground that there is an error in considering relevant date according to SEBI Circular CFD/DIL3/CIR/2017/21 dated March 10, 2017. 2. To consider and approve draft scheme of amalgamation of Lincoln Parenteral Limited ('Transferor Company') with Lincoln Pharmaceuticals Limited ('Transferee Company'), subject to necessary approvals. 3. Any other businesses with the permission of the Board.
03-12-2019
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Considered And Approved Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On September 30, 2019

 we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. on November 14, 2019 had considered following: 1. To Considered and Approved Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended on September 30, 2019; 2. The Limited Review Report on Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended on September 30, 2019. 3. Financial Highlights for the Quarter and Half Year Ended on September 30, 2019.
14-11-2019
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - For Considered And Approved Un-Audited Financial Results For The Quarter And Half Year Ended On September 30, 2019

 we would like to inform that the Board of Directors of the Company at their meeting held today, i.e. on November 14, 2019 had considered following: 1. To Considered and Approved Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended on September 30, 2019; 2. The Limited Review Report on Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended on September 30, 2019. 3. Financial Highlights for the Quarter and Half Year Ended on September 30, 2019.
14-11-2019
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Inter-Alia To Consider And Approve The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On September 30, 2019 Along With Any Other Business, If Any.

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2019 ,inter alia, to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter Ended on September 30, 2019 along with any other business, if any. Further, in continuation to our disclosure on Closure of Trading Window dated September 30, 2019, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct for Prevention of Insider Trading, it may be noted that the trading window has been closed for Designated Persons viz Directors, identified Employees, KMPs, Promoter and Promoter Group of the Company and its subsidiaries including Immediate Relatives of the Designated Persons of the Company and its subsidiaries and for the Connected Persons from September 30, 2019 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.
04-11-2019
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Minutes Of The 25Th Annual General Meeting Of The Company.

 Minutes of the 25th Annual General Meeting of the Members of the Company held held at 10:30 A.M. on Monday, the 30th day of September, 2019 at the Registered Office of the Company
26-10-2019
Bigul

Company news | Lincoln Pharmaceuticals

 Lincoln Pharmaceuticals has been awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray) by the Government of I
22-10-2019
Bigul

Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed a copy of press release dated October 22, 2019 titled "Lincoln Pharmaceuticals Limited receives a Patent for Diclofenac Rectal Spray."
22-10-2019
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015 For The Half Year Ended On September 30, 2019.

 With reference to the above cited subject, please find enclose herewith Half Yearly Compliance Certificate for the Period Ended on September 30, 2019 as required to be sent under Regulation 40 (9) of SEBI (Listing and Obligations Requirements) Regulations, 2015.
21-10-2019
Next Page
Close

Let's Open Free Demat Account